TriSalus Life Sciences (TLSI) EBT (2021 - 2026)

TriSalus Life Sciences (TLSI) has 6 years of EBT data on file, last reported at $1.5 million in Q1 2026.

• For the quarter ending Q1 2026, EBT rose 114.88% year-over-year to $1.5 million; the trailing twelve-month figure through Mar 2026 stood at -$27.3 million (changed 0.37% YoY), and the FY2025 full-year result was -$39.2 million, down 30.56% from the prior year.
• EBT for Q1 2026 stood at $1.5 million, up from -$9.8 million in the prior quarter.
• Across five years, EBT topped out at $2.8 million in Q1 2022 and bottomed at -$35.6 million in Q4 2023.
• The 5-year median for EBT is -$8.3 million (2025), against an average of -$9.0 million.
• Peak annual rise in EBT reached 1137.69% in 2022, while the deepest fall reached 878.25% in 2022.
• A 5-year view of EBT shows it stood at -$22.5 million in 2022, then slumped by 58.14% to -$35.6 million in 2023, then soared by 71.63% to -$10.1 million in 2024, then climbed by 3.52% to -$9.8 million in 2025, then jumped by 115.82% to $1.5 million in 2026.
• The last three EBT figures came in at $1.5 million (Q1 2026), -$9.8 million (Q4 2025), and -$10.8 million (Q3 2025), per Business Quant data.

Peer Comparison